Ability of six Latin American antivenoms to neutralize the venom of Mapana equis (Bothrops atrox) from Antioquia and Chocó (Colombia)

Otero, Rafael; Núñez, Vitelbina; Osorio, R.G.; Gutiérrez, José Marı́a; Giraldo, César Augusto Giraldo; Posada, L.E.

doi:10.1016/0041-0101(96)83735-4

Cited by 11 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Incubation of the venom at different temperatures indicated that the venom component responsible for hemolysis is thermolabile. Other biological activities of B. lanceolatus, such as rat paw edema, leukocyte migration and hemorrhagic activity, are also thermolabile (7,21,22 (16,(28)(29)(30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

In vitro hemolytic activity of Bothrops lanceolatus (fer-de-lance) venom

Martins¹,

Araújo²,

Bon³

et al. 2009

J. Venom. Anim. Toxins incl. Trop. Dis

View full text Add to dashboard Cite

Bothrops lanceolatus venom contains a variety of enzymatic and biological activities. The present work investigated the hemolytic activity of this venom and its phospholipase A 2 (PLA 2 ). Bothrops lanceolatus venom (6.7 µg/mL) caused indirect hemolysis of cow, horse, rat and sheep erythrocytes, with horse erythrocytes being the most sensitive; no direct hemolysis was observed. Hemolysis in sheep erythrocytes was concentration-dependent (5-11.7 µg/mL) and markedly attenuated by heating the venom for 30 minutes at ≥ 40°C and by the PLA 2 inhibitor p-bromophenacyl bromide. An acidic PLA 2 (5 µg/mL) purified from B. lanceolatus venom also caused hemolysis. This PLA 2 showed immunoprecipitin lines with antivenom against B. lanceolatus, which suggests that the enzymatic and hemolytic activities of this enzyme may be neutralized during antivenom therapy. These results indicate that B. lanceolatus venom and its PLA 2 can cause hemolysis in vitro.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro hemolytic activity of Bothrops lanceolatus (fer-de-lance) venom

Martins¹,

Araújo²,

Bon³

et al. 2009

J. Venom. Anim. Toxins incl. Trop. Dis

View full text Add to dashboard Cite

show abstract

“…In other cases, antivenoms are able to neutralize the venoms of species not used in the immunization of animals, but being phylogenetically related (WHO, 2010a). This phenomenon of immunological cross-reactivity has been clearly demonstrated, for instance, in the case of antivenoms raised against Bothrops sp venoms in Latin America (Otero et al, 1995;Segura et al, 2010a). In other cases, however, the cross-reactivity of antivenoms is low and, therefore, the efficacy of some products to neutralize venoms of medically-relevant species not included in immunization mixtures is limited, as occurs with venoms of some rattlesnakes and coral snakes in the Americas (Saravia et al, 2002;Tanaka et al, 2010).…”

Section: Clinical Performance Of Antivenoms: Efficacymentioning

confidence: 99%

Snakebite Envenoming: A Public Health Perspective

Gutiérrez¹

2012

Public Health - Methodology, Environmental and Systems Issues

View full text Add to dashboard Cite

“…When an anti-bothropic mAV and a pAV were prepared from the same manufacturer ie., INS of Columbia, it was found that the pAV was more potent than the mAV. Furthermore, Otero et al conducted a randomized double blind clinical trial of a mAV and a pAV prepared from the same manufacturer in Costa Rica (Otero et al, 1995). An mAV anti-B.…”

Section: Antivenom Potencymentioning

confidence: 99%

Merit and Demerit of Polyvalent Snake Antivenoms

Ratanabanangkoon

2003

Journal of Toxicology: Toxin Reviews

View full text Add to dashboard Cite

Polyvalent antivenoms contain specific antibodies capable of neutralizing a number of homologous venoms from different species/genera. They can save lives of victims of snake envenomations, even when the culprit snake has not been identified (the usual case, about 80% of the time), and a monovalent antivenom can not be chosen. They are useful in areas where there are too many poisonous species to produce monovalent antivenoms against all of them. It is now possible to prepare polyvalent antivenoms with high potencies comparable to those of the corresponding monovalent antivenoms. With good manufacturing processes, these antivenoms have been shown to cause few and minor adverse reactions. In addition, polyvalent antivenoms exhibit a wider range of paraspecific neutralization of venoms from different species/genera, even from distant geographic areas. Lastly, it is less expensive and easier to produce and handle a few polyvalent antivenoms than batteries of monovalent antivenoms.

show abstract

Ability of six Latin American antivenoms to neutralize the venom of Mapana equis (Bothrops atrox) from Antioquia and Chocó (Colombia)

Cited by 11 publications

References 0 publications

In vitro hemolytic activity of Bothrops lanceolatus (fer-de-lance) venom

In vitro hemolytic activity of Bothrops lanceolatus (fer-de-lance) venom

Snakebite Envenoming: A Public Health Perspective

Merit and Demerit of Polyvalent Snake Antivenoms

Contact Info

Product

Resources

About